Melanoma is one of highly aggressive kinds of skin cancer with a metastatic potential. Currently, melanoma treatment has been improved by a combination of therapies with targeted kinase inhibitors and immunotherapies, with radiation therapy (RT) reserved to the most advanced melanoma stage. Among different RT options, the Boron Neutron Capture Therapy (BNCT) is a modality which selectively destroys tumor cells leaving healthy ones almost intact. Its therapeutic effect depends mainly on the boron concentration in a cancer. Therefore, there is a need to find a ligand which transfers sufficient amount of boron to cancer cells and study their potential therapeutic activity in preclinical studies. Spheroids, which are 3D cell models are proposed to test nucleic acids as a boron carrier for BNCT to mimic 3D structure and microenvironment of cancer.